Syst-Eur

Syst-Eur

Cardiology A trial designed to evaluate the effectiveness of isolated antihypertensive therapy in preventing cardiovascular complications in elderly Pts with isolated systolic HTN. See Antihypertensive, Calcium channel blockers, Hypertension.
Mentioned in ?
References in periodicals archive ?
The Syst-Eur study [sup][17] enrolled 4695 patients older than 60 years with SBP 160 to 219 mmHg and DBP lower than 95 mmHg.
SHEP study, Syst-Eur study, and Syst-China study indicated that, for patients aged 60 years and above with SBP higher than 160 mmHg, lowering SBP to a level around 140–145 mmHg will significantly reduce the risk of cardiovascular and cerebrovascular events, as well as all-cause mortality.
Systolic hypertension in Europe (Syst-Eur) trial investigators, Prognostic significance of renal function in elderly patients with isolated systolic hypertension, results from the Syst-Eur trial.
In a Syst-Eur substudy of 492 diabetic patients with ISH, the dihydropyridine resulted in a 63% reduction in cardiac events, a 73% decrease in strokes, and a 76% drop in cardiovascular mortality.
In a Syst-Eur substudy of 492 diabetic patients with isolated systolic hypertension, the dihydropyridine calcium channel blocker resulted in a 63% reduction in cardiac events, a 73% decrease in strokes, and a 76% drop in mortality due to cardiovascular disease.
SYST-EUR, a major clinical trial on the calcium channel blocker (CCB) nimodipine found that subjects receiving the drug experienced 42% fewer strokes and 31% fewer cardiac events.
To date, there has been no definitive evaluation of the effect of antihypertensive therapy on elderly patients' quality of life, and future studies must specifically address this issue; this is one of the objectives of the SYST-EUR trial |20~, currently in progress, for ACE-inhibitors.
Nitrendipine was chosen as the comparator agent because of its success in the Syst-Eur study(2) where treatment reduced the risk of stroke by 42% in elderly patients with systolic hypertension.
The SHEP study, Syst-Eur study, STOP, and SCOPE were notable because they investigated antihypertensives in which population?
Weber commented further: "Two major international clinical trials that finished during the last couple of years, Syst-Eur and HOPE, dosed their principal cardiovascular drugs at night and reported significant survival benefits as well as reductions in serious events like strokes and heart attacks.
The Syst-Eur data are quite convincingly to the contrary, said Dr.